Jesus Mendiola-Precoma

Jesus Mendiola-Precoma

Auto-generated profile, based on publicly available information

Jesus Mendiola-Precoma

Escuela de Bachilleres de la Universidad Autónoma de Querétaro (México)

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in BioMed Research International
Verified
Journal Article
Open access
PDF file
JMJ. Mendiola-Precoma
J. Mendiola-Precoma
Laura C BerumenLaura C Berumen
Laura C Berumen
KPK. Padilla
K. Padilla
GGGUADALUPE GARCIA-ALCOCER
GUADALUPE GARCIA-ALCOCER
Alzheimer’s disease (AD) is the most common cause of dementia associated with a progressive neurodegenerative disorder, with a prevalence of 44 million people throughout the world in 2015, and this figure is estimated to double by 2050. This disease is characterized by blood-brain barrier disruption, oxidative stress, mitochondrial impairment, neuroinflammation, and hypometabolism; it is related to amyloid-βpeptide accumulation and tau hyperphosphorylation as well as a decrease in acetylcholine levels and a reduction of cerebral blood flow. Obesity is a major risk factor for AD, because it induces adipokine dysregulation, which consists of the release of the proinflammatory adipokines and decreased anti-inflammatory adipokines, among other processes. The pharmacological treatments for AD can be divided into two categories: symptomatic treatments such as acetylcholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists and etiology-based treatments such as secretase inhibitors, amyloid binders, and tau therapies. Strategies for prevention of AD through nonpharmacological treatments are associated with lifestyle interventions such as exercise, mental challenges, and socialization as well as caloric restriction and a healthy diet. AD is an important health issue on which all people should be informed so that prevention strategies that minimize the risk of its development may be implemented.

1 June 2020 in IBRO Reports
Verified
Journal Article
Open access
ARAlfredo Rodríguez-Cruz
Alfredo Rodríguez-Cruz
Antonio Romo-MancillasAntonio Romo-Mancillas
Antonio Romo-Mancillas
JMJesus Mendiola-Precoma
Jesus Mendiola-Precoma
JEJesica Esther Escobar-Cabrera
Jesica Esther Escobar-Cabrera
GGGuadalupe García-Alcocer
Guadalupe García-Alcocer
Laura C BerumenLaura C Berumen
Laura C Berumen
Parkinson´s disease is the most important neuromotor pathology due to the prominent loss of dopaminergic neurons in the substantia nigra pars compacta. There is an inherent deficiency of dopamine in Parkinson´s disease, which is aggravated when neuroinflammatory processes are present. Several biomolecules are interesting candidates for the regulation of inflammation and possible neuroprotection, such as valerenic acid, one of the main components of Valeriana officinalis. A 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (MPTP)-induced mouse model of Parkinson's disease was developed to evaluate the motor effects of valerenic acid. The evaluation was carried out with four tests (an invert screen test for muscle strength, cross beam test, open field mobility test and lifting on hind legs test). Subsequently, the neuroinflammatory process was evaluated through ELISA of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α and IFN-γ). The decreases in the inflammatory and neurodegenerative processes were evaluated by Western blot and immunohistochemistry analyses of the tissues, which included an evaluation of the tyrosine hydroxylase and GFAP proteins. Finally, the predicted mechanism of action of valerenic acid was supported by molecular docking calculations with the 5-HT5A receptor. The results indicate that the use of valerenic acid as a co-treatment decreases the neuroinflammation in Parkinson's disease induced by MPTP and provides evidence of a decrease in the evaluated pro-inflammatory cytokines and in the amount of GFAP in the mesencephalic area. Valerenic acid prevents neuroinflammation in a Parkinson's disease mouse model, which might reflect the neuroprotection of dopaminergic neurons with the recovery of motor ability.

5 September 2022 in Revista Tecnología, Ciencia y Educación
Verified
Journal Article
Open access
PDF file
LRLuis Alberto Soto Reyes
Luis Alberto Soto Reyes
ACAlfredo Rodríguez Cruz
Alfredo Rodríguez Cruz
RCRita Ochoa Cruz
Rita Ochoa Cruz
JMJesus Mendiola-Precoma
Jesus Mendiola-Precoma
JGJosé Eduardo Rodríguez Guevara
José Eduardo Rodríguez Guevara
ZYZulma Yunue Cajiga Yañez
Zulma Yunue Cajiga Yañez
Hoy en día, en la educación, la tecnología de realidad aumentada es una herramienta con gran potencial debido a que permite a los docentes y al alumnado (hombres y mujeres) abordar de una manera más dinámica el tema de estudio, de tal forma que el objetivo de la presente investigación abarca el diagnóstico de la comprensión y uso de la realidad aumentada en una muestra de la población institucional de la Escuela de Bachilleres de la Universidad Autónoma de Querétaro. Los resultados sugieren que se tiene un mínimo conocimiento respecto a la implementación y gestión de esta tecnología como parte de las estrategias de enseñanza-aprendizaje, motivo por el cual esta herramienta, actualmente, tiene un escaso uso en el proceso de enseñanza. Con respecto a lo anterior, se propone la creación de entornos de aprendizaje que integren la realidad aumentada para así aspirar a aumentar la comprensión de los temas de estudio.